Osteosarcoma of the jaw – experience at the Medical University Vienna and comparative study with international tumor registries

Authors

  • Christina Eder-Czembirek Medical University Vienna, Maxillofacial and Oral Surgery, Department of Cranio
  • Doris Moser Medical University Vienna, Maxillofacial and Oral Surgery, Department of Cranio
  • Simone Holawe Medical University Vienna, Maxillofacial and Oral Surgery, Department of Cranio
  • Thomas Brodowicz Medical University of Vienna, Department of Internal Medicine I
  • Jutta Ries Erlangen University Hospital, Department of Oral and Maxillofacial Surgery
  • Irene Sulzbacher Medical University of Vienna, Clinical Institute of Pathology
  • Edgar Selzer University Clinic of Radiotherapy, Medical University of Vienna https://orcid.org/0000-0003-2031-2768

DOI:

https://doi.org/10.6061/clinics/2019/e701

Keywords:

Osteosarcoma, Jaw, MAGE-A, Immunohistochemistry

Abstract

OBJECTIVES: Osteosarcoma of the jaw (OSAJ) is fundamentally different in clinical practice from its peripheral counterparts. Studies are difficult to conduct due to low incidence rates. The primary aim of this study was to provide for the first time a comprehensive retrospective analysis of the treatment concepts and outcome data of OSAJ patients treated at the University Hospital Vienna and to compare these with two recently published studies on OSAJ. The clinical study was accompanied by a biomarker study investigating the prognostic relevance of melanoma-associated antigen-A (MAGE-A) in OSAJ specimens. METHOD: Eighteen patients were included, and their outcomes were compared to published data. Immunohistochemistry was performed with mouse monoclonal antibodies against MAGE-A. Survival rates were estimated by the Kaplan-Meyer method. The log-rank test was used to analyze potential prognostic parameters. Fisher’s exact test was performed to define the significant differences between the survival rates of the current study and the DOESAK registry. RESULTS: Disease-specific survival was 93.8% after five and 56.3% after ten years. The development of metastases (p=0.033) or relapse (p=0.037) was associated with worsened outcomes in our group as well as in the comparative group. Despite the different treatment concepts of the study groups, survival rates were comparable. MAGE-A failed to show prognostic relevance for OSAJ patients. CONCLUSIONS: Uncertainties about the optimal treatment strategies of OSAJ patients will currently remain. Thus, prospective studies of OSAJ are needed but are only feasible in a multicenter study setting, conducted over a prolonged time period.

Downloads

Download data is not yet available.

Downloads

Published

2019-05-14

How to Cite

Eder-Czembirek, C., Moser, D., Holawe, S., Brodowicz, T., Ries, J., Sulzbacher, I., & Selzer, E. (2019). Osteosarcoma of the jaw – experience at the Medical University Vienna and comparative study with international tumor registries. Clinics, 74, e701. https://doi.org/10.6061/clinics/2019/e701

Issue

Section

Original Articles